UNIVERSITY OF FUKUI

Medtronic's PulseSelect Demonstrates Durable Lesion Formation in Atrial Fibrillation Treatment

8 months ago

• Medtronic's PulseSelect pulsed field ablation (PFA) system shows 98% durable pulmonary vein isolation in AFib patients, according to a new study. • The study, presented at APHRS, highlights the system's efficacy with 96% of patients achieving isolation in all veins, approximately two months post-ablation. • PulseSelect continues global expansion with approvals in China and Australia, and launch in Japan following reimbursement approval, increasing patient access. • The procedure averages 36 minutes, conducted without fluoroscopy, showcasing efficiency and reduced radiation exposure.